Radiopharmaceuticals Market Research Report - Global Forecast till 2027

Radiopharmaceuticals Market: Information by Type (Diagnostic (SPECT Radiopharmaceuticals, PET Radiopharmaceuticals) and Therapeutic), Application (Neurology, Cardiology, Oncology and others) and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Global Forecast till 2027

ID: MRFR/Pharma/1119-CR | February 2021 | Region: Global | 203 pages

Market overview 


Nuclear medicine is a revolutionary therapy in the healthcare sector. Nuclear medicine therapy using radiopharmaceuticals is gaining popularity every year. It is a medication that contains radioisotopes that used as both a diagnosis medication and a therapeutic agent. The advancements in this sector have to lead to plenty of successful treatments. Radio-pharmaceuticals are a therapy that manages both chronic and critical diseases. Radio-pharmaceuticals are widely used in molecular imaging as a biomarker. Also, there are several diagnostics for targeted organ with nuclear medicine radiopharmaceuticals.


 During the radiopharmaceuticals, the SPECT and the PET techniques are widely used. The cost-effectiveness, noninvasiveness, high sensitivity and ease of diagnosis are some of the specialties of radiopharmaceuticals. The clinical applications of radiopharmaceuticals are oncology, cardiology, thyroid, tumour and lymphoma. Radiopharmaceuticals are popular due to their low-cost diagnosis. Due to all these benefits of radiopharmaceuticals, its requirement is increasing in the medical field. As per the pharmaceutical market research reports, the growth rate of this market is expected to be 8.10%. Also, the pharmaceutical market value is estimated as 15.060.87 during the forecast year 2025. 


Covid analysis 


Covid 19 outbreak has caused several damages to most of the global industries. In the medical sector, there is massive research happening to find an effective vaccine for the virus. There is wide use of different pharmaceutical products during the pandemic. The global pharmaceutical market size is growing due to the virus outbreak. The surging trends will continue till the forecast year 2025. Early detection of radiopharmaceuticals is helping health advisers to diagnose any illness at the primary stage. It is assisting the health advisers to provide quick treatments for heart, bone and cancer patients. During the covid 19, the market faced several disruptions in the demand and supply of the product. The manufacturing process is resuming that increases the demand for the market. Moreover, the requirement for radiopharmaceuticals has grown due to the prevalence of online pharmacy services. 


Market dynamics 



  • The crucial market drivers 


The radiopharmaceutical is considered the fastest-growing segment in the pharmaceutical industry. The increasing awareness about the early and timely diagnosis by radiopharmaceutical therapy is the crucial market driver. Today, radiopharmaceuticals are widely used to diagnose chronic illness. The prevalence of chronic illness is high due to the unhealthy lifestyle of individuals. Also, the positive results of radiopharmaceutical in treating this chronic illness are driving more demand for the market.


Moreover, the versatile application of radiopharmaceuticals is another crucial market driving factor for this market. Through immense research and development, the healthcare industry can use radiopharmaceuticals for plenty of medical reasons. The high R&D is constantly developing the radiopharmaceutical market. Moreover, the technological advancement in the medical field is another factor that fuels the demand for radiopharmaceuticals. This high-end therapy is essential to treat chronic diseases at an early stage. With the advancing technological innovation in medical devices, the demand for radiopharmaceuticals grows in the forecast period. 



  • The market growth opportunities 


The radiopharmaceutical market has plenty of new product launches and developments. The robust development offers tons of future radiopharmaceutical market growth opportunities. Due to the prevalence of cancer, there is high demand for nuclear imaging technology. There are new types of radiopharmaceuticals that enable the diagnosis of cancer and oncology.


Also, the pharmaceutical applications of radioisotopes are increasingly contributing to further growth opportunities. These factors in the market offer promising growth opportunities in the upcoming years. Several key players in the market are creating future growth opportunities by providing new developments. Also, the key players are planning to launch the new therapeutics of radiopharmaceuticals in the next year. Moreover, the developments of medical infrastructure in many regions accelerate the growth opportunities. With the rising infrastructural development, the use of radiopharmaceuticals will be more prevalent. 



  • The market restraints 


The slow adoption rate of radiopharmaceuticals is a major restraint in this market. Radiopharmaceuticals are a high-end technology. It is can easily detect chronic illness and help in early diagnosis. The market needs to increase the product awareness. The lack of awareness is causing less adoption rate in this market. The less adoption rate of this technology can slow down the overall growth rate of the market.


Moreover, the half-life of radiopharmaceuticals is another restraining factor in this market. Radiopharmaceuticals are a high investment. The half-life or the short expectancy of it is a crucial factor that restricts the market demand. Many purchasers are hesitant due to the low life expectancy of the technology. As per the pharmaceutical market report, the restraints demand a declining effect on the radiopharmaceutical market during the forecast period. 



  • The market challenges  


With high-end technology, individuals expect cost-effectiveness. The function of radiopharmaceuticals is exceptional. However, the high cost poses a major challenge to this market. Only the developed regions can adapt to radiopharmaceuticals due to high spending power. However, the undeveloped regions and small medical firms find it difficult to afford the product. The cost of radiopharmaceuticals can slightly decline the market growth in the forecast period. 



  • The cumulative growth analysis 


Radiopharmaceutical is a surging market with plenty of growth potentials. The market drivers will contribute more to the overall market development during the forecast year. The growth Opportunities of this market look promising. In the upcoming years, the adoption rate of radiopharmaceuticals will substantially grow. However, there is a serious need to fix the cost challenges in this market. The market requires cost-effectiveness to attract customers from all regions. Also, there is a need to accelerate the awareness of radiopharmaceuticals in the upcoming years. As per the radiopharmaceutical market analysis, the market shows a positive trend that will continue till the forecast year 2025. 



  • The value chain analysis 


North America holds the largest radiopharmaceutical market share. The adoption rate of nuclear medicine is high in this region. Also, the usage of advanced therapeutic technologies is growing in this region. Also, North America is well known for its high purchasing power. All these factors are contributing to the massive growth rate of radiopharmaceuticals in this region. Moreover, the prevalence of cancer and cardiovascular are propelling the overall growth of the US radiopharmaceutical company. The well established key players in this region are launching a new product and expanding the market during the forecast year. 


Market segment 


By product 



  • TL-201

  • I-123

  • TC-99m

  • GA-67

  • SR-82/RB-82

  • F-18

  • RA-223

  • Re-186

  • Lu-117

  • I-131

  • SM-153

  • Y-90

  • Iridium-192

  • Cesium-131

  • Iodine-125

  • Palladium-103


By application 



  • Endocrine Tumor

  • Neurology

  • Bone Metastasis

  • Oncology

  • Lymphoma

  • Thyroid


Regional outlook 


North America 



  • Canada

  • S


Asia pacific 



  • India

  • South Korea

  • China 

  • Japan 

  • Singapore 

  • Malaysia 

  • New Zealand 


Middle East 



  • Turkey 

  • Saudi Arabia 

  • Israel 

  • South Africa 


Latin America 



  • Mexico 

  • Argentina 

  • Brazil 


Europe 



  • Spain 

  • France 

  • Germany 

  • UK 

  • Russia 

  • Netherlands 

  • Italy 


Regional analysis 


The radiopharmaceutical market is diversified into North America, Asia Pacific, Middle East, Latin America and Europe. High R&D investments are the crucial factor for the overall growth in the regional market. Also, Europe is a highly developing market with more research on medical isotopes.


The governmental support in the European region is driving more demand for the market. Also, the Asia Pacific is the fastest growing regional market. The increasing geriatric rate is raising the demand for nuclear medicine in this region. The Middle East and the Latin American region are the fastest emerging markets in the radiopharmaceuticals industry. The regional players are making several product innovations in radiopharmaceuticals. Some of the key players in this market are taking plenty of cost-cutting measures to increase the growth rate during the forecast period. 


Competitive landscape 


The radiopharmaceutical market is less competitive. However, the entry of new radiopharmaceutical companies will make the market more competitive in the upcoming years. The key market players are planning several market acquisitions and expansion plans in the upcoming years. 


The key players of the radiopharmaceutical market are 



  • GE healthcare 

  • Cardinal health 

  • Jubilant life sciences

  • Norgine B.V 

  • Curium 

  • Bracco diagnostic   

  • Lantheus Medical imaging 

  • Novartis AG 

  • Siemens healthiness 

  • JSC isotopes 

  • Curium 

  • Australian Nuclear Science and Technology


Recent developments 



  • The Lantheus is acquired as the leading imaging and diagnosis centre in this region. It is a step to expand their market in the forecast period. 

  • The radioisotope in Japan announces several new partnerships around the country. The specializing technologies are used in several chronic disease diagnostic procedures.

  • The key players of the market are expanding the research of radiopharmaceutical technology. It is a measure to widen the application uses of the technology.  


Report overview 



  1. Market overview highlights 

  2. Analysis based upon COVID 19

  3. Explanation upon the Market Dynamics

  4. Value chain analysis

  5. Market segmentation overview

  6. The regional analysis

  7. Competitive landscape analysis

  8. Recent Developments



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2025: USD 15,060.87 Million
  • 2027: Significant Value
  •   CAGR   8.10% (2019-2025)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Type, Application
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   GE Healthcare, Lantheus Medical Imaging, Inc., Novartis AG, BWX Technologies, Inc., Siemens Healthineers, IRE ELiT, JSC Isotope, NTP Radioisotopes SOC Ltd, Curium, Australian Nuclear Science and Technology Organization (ANSTO)
      Key Market Opportunities   New product launches and R&D Amongst major key Players
      Key Market Drivers

  • Increasing prevalence of chronic diseases
  • Increasing application of radiopharmaceuticals for the diagnosis & treatment of chronic diseases
  • Tthe technological advancements


  • Frequently Asked Questions (FAQ) :


    Radiopharmaceutical Market is projected to grow at an 8.7% CAGR between 2014-2023.

    Radiopharmaceutical Market is predicted to touch USD 10,473.88 million by 2023.

    Americas are predicted to have the largest share in the Radiopharmaceutical Market.

    Rising incidence of chronic diseases especially cancer and cardiovascular diseases and increasing expenditure on oncology medicine are boosting market growth.

    Strict regulations to manufacture radiopharmaceuticals and side effects resulting from radiopharmaceuticals may restrict market growth.